COMPLEX-INDUCED PROXIMITY EFFECTS IN ENOLATE FORMATION. HIGHLY DIASTEREOSELECTIVE α-METHYLATION OF BINAPHTHYL ESTERS OF ARYLACETIC ACIDS.

Kaoru Fuji,^{a*} Manabu Node,^b and Fujie Tanaka^a Institute for Chemical Research,^a Kyoto University, Uji, Kyoto 611, Japan. Kyoto Pharmaceutical University,^b Yamashina-ku, Kyoto 607, Japan

Abstract: Highly diastereoselective methylation of binaphthyl esters of arylacetic acids and its application to the syntheses of antiinflammatory drugs, (S)- suprofen and (S)-naproxen.

Recently, we reported a synthesis of optically active 2-arylalkanoic acids via diastereoselective alkylation of enolates generated from binaphthyl esters of arylacetic acids in tetrahydrofuran (THF)-hexamethylphosphoramide (HMPA).¹ Though a high degree of diastereoselectivity was recognized with bulky alkylating agents such as isopropyl iodide, less bulky alkylating agents resulted in a lower ratio of the products. Since 2-arylpropionic acids are an important class of nonsteroidal antiinflammatory drugs,² increase in diastereoselectivity of methylation has been desired to yield these drugs in optically pure form. Here, we report a dramatic improvement of diastereoselectivity in methylation, when n-butyllithium was used as a base in THF.


Generally, *n*-butyllithium has not been used for α -deprotonation of esters due to its nucleophilicity.³ We were delighted to find that binaphthyl ester 1 was deptotonated with *n*-butyllithium in THF and gave the methylated product 2 in high diastereomeric ratio rich in (R^*, R^*) -isomer.⁴ Results are listed in the Table.

A question to be answered is why *n*-butyllithium can be used as a base in the present enolization. Methylation of 3 and 4 under the standard conditions 4,6 afforded 5 and 6 in 60% and 25% yield, respectively. A 25% yield of 7 was obtained in the latter case indicating that approximately half of *n*-butyllithium was employed as a nucleophile rather than a base. 2-Naphthylester 9, lacking a top half of binaphthol, was not deprotonated smoothly but afforded an approximately 1:1 mixture of 8 and 10. External addition of 2-naphthol (11) gave similar results, indicating that an internal oxygen function is indispensable for the observed deprotonation of binaphthyl esters 1. Complex-induced proximity effects⁷ explain unexpectedly smooth enolization. Thus, *n*-butyllithium forms a complex with the oxygen function at C-2' in binaphthol prior to deprotonation. An enhanced acidity

OH 1) n-BuLi / THF		/ THF	OH Me	
	Ar 2) Mel			Ar O
Ar	temp, °C	time, h	yield,%	R*,R* : R*,S*
	-78	4.0	86	96:4
–∕_)–осн₃	-78~-25	4.3	72	87:13 ^a
{}-сі	-78~-30	2.0	97	92:8 ^b
-<->	-78~-30	3.5	78	95 : 5
\mathbf{i}	-78~-30	4.0	76	93:7

Table. Diastereoselective Methylation of Binaphthyl Esters 1 of Arylacetic Acids.

^a A ratio of 53:47 with LDA in THF/HMPA was reported. See ref. 1. ^b See ref. 5.




6554

of a proton at the α -position of esters is also important, because binaphthyl esters 12 and 13 failed in methylation under standard conditions.⁸


Although the detailed mechanism remains to be studied, an intermediate (E)enolate 14⁹ captured by two lithium atoms offers a plausible explanation for the observed stereoselectivity in methylation. The *si*-face of the nucleophilic carbon in 14 is more congested due to the H-3 than the *re*-face, when (R)-binaphthol is used as a chiral auxiliary.

Scheme. Synthesis of (S)-(+)-Suprofen (19).



a)TBSCI, b)*n*-BuLi/2-thiophenecarboxaldehyde, c)Jones' oxid, d)ethylene glycol/TsOH, e)NaOH f)R*OH/WSC/DMAP, g)*n*-BuLi/THF,MeI, h)LiOH, i)HCI. (R*OH = (S)-2,2'-binaphthol).

Diastereoselective methylation of binaphthyl esters was applied to the syntheses of clinically important antiinflammatory drugs, (S)-suprofen $(19)^{11}$ and (S)-naproxen (21).¹² A synthetic route to (S)-suprofen (19) utilized acetalization of an aromatic ketone 15, prepared from 4-bromophenethyl alcohol in three steps, to yield 16 (Scheme). Esterification with (S)-binaphthol gave a desired ester 17, which was alkylated to afford a 95% yield of 18 contaminated with 2% of S, R-isomer. Hydrolysis with lithium hydroxide followed by the treatment with acid yielded (S)-(+)-suprofen $(19)^{13}$ of 93% ee¹⁴ ($[\alpha]_D^{28}$ +39.5°, CHCl₃). (S)-(+)-Naproxen $(21)^{14}$ of 82% ee¹³ ($[\alpha]_D^{28}$ +52.6°, CHCl₃) was prepared by the diastereoselective methylation (94%, 92:8) of 20 followed by the basic hydrolysis.



References and Notes

- 1. K. Fuji, M. Node, F. Tanaka, and S. Hosoi, Tetrahedron Lett., 1989, 30, 2825.
- T. Y. Shen, Angew. Chem. Int. Ed. Engl., 1972, 11, 460. J. P. Rieu, A. Boucherle, H. Cousse, and G. Mouzin, Tetrahedron, 1986, 42, 4095.
- 3. An enolate of a sterically congested ester has been prepared with *n*-butyllithium. See, D. Seebach, R. Amstutz, T. Laube, W. B. Schweizer, and J. D. Dunitz, J. Am. Chem. Soc., 1985, 107, 5403.
- 4. Typical procedure : To a solution of binaphthyl ester 1 (Ar = Ph, 0.2 mmol) in anhydrous THF (3 mL) was added a solution of *n*-butyllithium in hexane (1.57 M, 2.1 eq.) at -78°C. After 5 min., methyl iodide (20 eq.) was added and the mixture was stirred at -78°C for 4 h. Usual extractive workup followed by preparative TLC (silica gel, AcOEt : hexane = 1 : 3.5) gave a 86% yield of 2 (Ar = Ph). The diastercomeric ratio was shown to be 96:4 by ¹H NMR measurement, which was consistent with that of crude extracts.
- 5. Alkylation with *i*-propyl iodide afforded a 96:4 mixture of R^*, R^* and R^*, S^* isomers in 80% yield. Addition of HMPA is indispensable to prevent the decomposition of an enolate.
- 6. A 1.1 eq. of *n*-butyllithium was used.
- 7. P. Beak and A. I. Meyers, Acc. Chem. Res., 1986, 19, 356.
- 8. 2,2'-Binaphthol was obtained in high yield.
- 9. Though exclusive formation (E)-enolates from esters with LDA in THF is well known,⁹ conclusive evidence for the formation of the same enolate with *n*-butyllithium has not been obtained. However, the chelated (Z)-enolate cannot explain the observed stereochemistry.
- 10. R. E. Ireland, R. H. Mueller, and A. K. Willard, J. Am. Chem. Soc., 1976, 98, 2868.
- P. A. Janssen, Arzneim.-Forsch., 1975, 25, 1495. R. S. Capetola and D. A. Rosenthale, J. Pharmacol. Exp. Ther., 1980, 214, 16. R-S. Pujalte, E. Valdez, and R. De la Paz, Curr. Ther. Res. 1984, 36, 245.
- 12. I. T. Harrison, B. Lewis, P. Nelson, W. Rooks, A. Roszokowski, A. Tomolonis, and J. H. Fried, J. Med. Chem., 1970, 13, 203.
- 13. S. H. Wu, Z.-W. Guo, and C. J. Sih, J. Am. Chem. Soc., 1990, 112, 1990.
- 14. Determined by HPLC analysis of its anilide with a chiral column.
- 15. C. Giordano, G. Castaldi, S. Cavicchioli, and M. Villa, Tetrahedron, 1989, 45, 4243.

(Received in Japan 30 July 1990)